{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:31:38Z","timestamp":1781710298092,"version":"3.54.5"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.gene.2021.145533","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T16:16:39Z","timestamp":1614096999000},"page":"145533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency"],"prefix":"10.1016","volume":"782","author":[{"given":"Loubna","family":"Oumeslakht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Ababou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouabid","family":"Badaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Qmichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2021.145533_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.meegid.2013.05.013","article-title":"Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines","volume":"18","author":"Ahmed","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.gene.2021.145533_b0010","unstructured":"AIHW, Australian Institute of Health and Welfare, 2016. Cervical screening in Australia 2013-2014. Cancer series no 97. Cat. No. CAN 95."},{"key":"10.1016\/j.gene.2021.145533_b0015","unstructured":"AIHW, Australian Institute of Health and Welfare 2018. Cervical screening in Australia 2018. Cat. No. CAN 111."},{"key":"10.1016\/j.gene.2021.145533_b0020","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programmes: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"Br. Med. J."},{"issue":"32","key":"10.1016\/j.gene.2021.145533_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0968-8080(08)32415-X","article-title":"Cervical cancer: the sub-Saharan African perspective","volume":"16","author":"Anorlu","year":"2008","journal-title":"Reprod. Health Matters"},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virol.2005.04.022","article-title":"Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1regions","volume":"338","author":"Arias-Pulido","year":"2005","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.gene.2021.145533_b0035","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/01.ogx.0000221187.63574.5c","article-title":"Vaccines for the prevention of Human Papillomavirus and associated gynecologic diseases: a review","volume":"61","author":"Ault","year":"2006","journal-title":"Obstet. Gynecol. Surv."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01443615.2018.1493441","article-title":"New prophylactics human papilloma virus (HPV) vaccines against cervical cancer","volume":"39","author":"Barra","year":"2019","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.gene.2021.145533_b0045","doi-asserted-by":"crossref","first-page":"s333","DOI":"10.2741\/1003","article-title":"A review of human papillomavirus vaccines: from basic science to clinical trials","volume":"8","author":"Berry","year":"2003","journal-title":"Front. Biosci."},{"key":"10.1016\/j.gene.2021.145533_b0050","doi-asserted-by":"crossref","first-page":"31803","DOI":"10.1074\/jbc.M706380200","article-title":"Crystal structures of four types of HPV L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies","volume":"281","author":"Bishop","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.gene.2021.145533_b0055","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1128\/JVI.00842-15","article-title":"Naturally occurring capsid protein variants of human papillomavirus genotype 31 represent a single L1 serotype","volume":"89","author":"Bissett","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.gene.2021.145533_b0060","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.10.003","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.gene.2021.145533_b0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bpobgyn.2017.08.010","article-title":"Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage","volume":"47","author":"Brotherton","year":"2018","journal-title":"Best Pract. Res. Clin. Obstetr. Gynaecol."},{"key":"10.1016\/j.gene.2021.145533_b0070","unstructured":"Bruni, L., Albero, G., Serrano, B., Mena, M., G\u00f3mez, D., Mu\u00f1oz, J., Bosch, FX., de Sanjos\u00e9, S., 2019. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019."},{"key":"10.1016\/j.gene.2021.145533_b0075","unstructured":"Bruni, L., Albero, G., Serrano, B., Mena, M., G\u00f3mez, D., Mu\u00f1oz, J., Bosch, F.X., de Sanjos\u00e9, S., ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Africa. Summary Report 17 June 2019."},{"issue":"1\u20132","key":"10.1016\/j.gene.2021.145533_b0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.virol.2013.05.038","article-title":"The papillomavirus major capsid protein L1","volume":"445","author":"Buck","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.gene.2021.145533_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/9781555819040.ch8","article-title":"Human papillomavirus","volume":"177\u2013195","author":"Burd","year":"2016","journal-title":"Diagnos. Microbiol. Immunocompromised Host"},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0090","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jmv.20492","article-title":"Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies","volume":"77","author":"Carpentier","year":"2005","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.gene.2021.145533_b0095","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/JVI.80.10.4664-4672.2006","article-title":"Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera","volume":"80","author":"Carter","year":"2006","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.gene.2021.145533_b0100","doi-asserted-by":"crossref","first-page":"11625","DOI":"10.1128\/JVI.77.21.11625-11632.2003","article-title":"Identification of a human papillomavirus type-16-specific epitope on the C-terminal arm of the major capsid protein L1","volume":"77","author":"Carter","year":"2003","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.gene.2021.145533_b0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jmv.21552","article-title":"Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions","volume":"81","author":"Cento","year":"2009","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.gene.2021.145533_b0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1097-2765(00)80449-9","article-title":"Structure of small virus-like particles assembled from the L1 protein of Human Papillomavirus 16","volume":"5","author":"Chen","year":"2000","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12985-016-0629-9","article-title":"L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis","volume":"13","author":"Chen","year":"2016","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0120","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2214-109X(18)30405-4","article-title":"A call for the introduction of gender-neutral HPV vaccination to national immunisation programmes in Africa","volume":"7","author":"Chido-Amajuoyi","year":"2019","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13337-015-0295-3","article-title":"Genetic variability and phylogeny analysis of partial L1 gene of human papillomavirus variants in Buenos Aires, Argentina","volume":"27","author":"Chiesa","year":"2016","journal-title":"VirusDisease"},{"issue":"2","key":"10.1016\/j.gene.2021.145533_b0130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.2001.1220","article-title":"Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types","volume":"291","author":"Christensen","year":"2001","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.gene.2021.145533_b0135","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/jmv.21777","article-title":"Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35","volume":"82","author":"Cornut","year":"2010","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.gene.2021.145533_b0140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ygyno.2004.05.037","article-title":"Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands","volume":"94","author":"De Boer","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gene.2021.145533_bib406","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.","volume":"8","author":"de Martel","year":"2020","journal-title":"The Lancet Global Health"},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0145","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0150","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/cid\/ciz135","article-title":"Principal controversies in vaccine safety in the United States","volume":"69","author":"De Stefano","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.gene.2021.145533_b0155","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","article-title":"HPV vaccine cross-protection: Highlights on additional clinical benefit","volume":"130","author":"De Vencenzo","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"De Villiers","year":"2004","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-09842-6","article-title":"Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection","volume":"7","author":"Di Paola","year":"2017","journal-title":"Sci. Rep."},{"issue":"08","key":"10.1016\/j.gene.2021.145533_b0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.6026\/97320630013241","article-title":"Naturally occurring capsid protein variants L1 of human papillomavirus genotype 16 in Morocco","volume":"13","author":"El-Aliani","year":"2017","journal-title":"Bioinformation"},{"key":"10.1016\/j.gene.2021.145533_b0175","doi-asserted-by":"crossref","unstructured":"Fernandes, J.V., De Medeiros Fernandes, T.A.A., 2012. Human Papillomavirus: biology and pathogenesis. In: Human Papillomavirus and Related Diseases-From Bench to Bedside-A Clinical Perspective. IntechOpen. https:\/\/doi.org\/10.5772\/27154.","DOI":"10.5772\/27154"},{"issue":"2","key":"10.1016\/j.gene.2021.145533_b0180","article-title":"Long term immunogenicity and effectiveness of the 9-valent HPV vaccine in preadolescents and adolescents","volume":"144","author":"Finalle","year":"2019","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0185","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00705-006-0734-y","article-title":"Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31","volume":"151","author":"Fleury","year":"2006","journal-title":"Arch. Virol."},{"issue":"7","key":"10.1016\/j.gene.2021.145533_b0190","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/pro.156","article-title":"Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications","volume":"18","author":"Fleury","year":"2009","journal-title":"Protein Sci."},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0195","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.meegid.2011.06.014","article-title":"Genetic variability in the major capsid L1 protein of Human papillomavirus type 16 (HPV-16) and 18 (HPV-18)","volume":"11","author":"Frati","year":"2011","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.gene.2021.145533_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fonc.2019.00355","article-title":"Mucosal and cutaneous human papillomavirus infections and cancer biology","volume":"9","author":"Gheit","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2021.145533_bib407","author":"GLOBOCAN","year":"2019","journal-title":"International agency for research on cancer"},{"issue":"7","key":"10.1016\/j.gene.2021.145533_b0205","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1099\/jgv.0.000829","article-title":"Impact of naturally occuring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies","volume":"98","author":"Godi","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.gene.2021.145533_b0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.virol.2015.04.016","article-title":"Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization","volume":"483","author":"Guan","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.gene.2021.145533_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/130828","article-title":"Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North-East Brazil","volume":"2015","author":"Gurgel","year":"2015","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0220","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","volume":"4","author":"Hall","year":"2019","journal-title":"Lancet Public Health"},{"issue":"12","key":"10.1016\/j.gene.2021.145533_b0225","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00284-018-1439-7","article-title":"Cervical cancer induction enhancement potential of Chlamydia trachomatis: a systematic review","volume":"75","author":"Karim","year":"2018","journal-title":"Curr. Microbiol."},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0230","doi-asserted-by":"crossref","first-page":"e0152782","DOI":"10.1371\/journal.pone.0152782","article-title":"Genetic diversity in the major capsid L1 protein of HPV-16 and HPV-18 in the Netherlands","volume":"11","author":"King","year":"2016","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.gene.2021.145533_b0235","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.meegid.2012.05.004","article-title":"Variations of human papillomavirus type 58 E6, E7, L1 genes and long control region in strains from women with cervical lesions in Liaoning province, China","volume":"12","author":"Liu","year":"2012","journal-title":"Infect. Genet. Evol."},{"issue":"10","key":"10.1016\/j.gene.2021.145533_b0240","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35- year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0245","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jmv.25675","article-title":"Characterization of major capsid protein (L1) variants of Human papillomavirus type 16 by cervical neoplastic status in Indian women: phylogenetic and functional analysis","volume":"92","author":"Mane","year":"2020","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0250","first-page":"465","article-title":"AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix)","volume":"71","author":"Mckeage","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.gene.2021.145533_b0255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"issue":"6","key":"10.1016\/j.gene.2021.145533_b0260","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.gene.2021.145533_b0265","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/infdis\/jix274","article-title":"Naturally occurring single amino acid substitution in the L1 major capsid protein of human papillomavirus type 16: alteration of susceptibility to antibody-mediated neutralization","volume":"216","author":"Ning","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms13010001","article-title":"Genetic variability and phylogeny of high risk HPV type 16, 18, 31, 33 and 45 L1 gene in Greek women","volume":"13","author":"Ntova","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0275","doi-asserted-by":"crossref","first-page":"e104374","DOI":"10.1371\/journal.pone.0104374","article-title":"Synergistic effect of viral load and alcohol consumption on the risk of persistent high-risk human papillomavirus infection","volume":"9","author":"Oh","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.gene.2021.145533_b0280","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/JCM.02202-07","article-title":"Human papillomavirus type 16 variant analysis of E6, E7 and L1 genes and long control region in biopsy samples from cervical cancer patients in north India","volume":"46","author":"Pande","year":"2008","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijc.24322","article-title":"Molecular variants of HPV-16 associated with cervical cancer in Indian population","volume":"125","author":"Pillai","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"32","key":"10.1016\/j.gene.2021.145533_b0290","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0295","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.vaccine.2020.01.024","article-title":"The science of vaccine safety: summary of meeting at Wellcome Trust","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.gene.2021.145533_b0300","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2021.145533_b0305","doi-asserted-by":"crossref","unstructured":"Rahman, M., Mia, A.R., Haque, S.E., Golam, M., Purabi, S.N., Choudhury, S.A.R. 2012. Beating cervical cancer in the developed countries: a dream or a reality?. Curr. Topics Public Health, 341. https:\/\/dx.doi.org\/10.5772\/52881.","DOI":"10.5772\/52881"},{"issue":"10","key":"10.1016\/j.gene.2021.145533_b0310","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/BF01384349","article-title":"Sequence variation in the L1 gene of human papillomavirus type 16 from Africa","volume":"140","author":"Ramesar","year":"1995","journal-title":"Arch. Virol."},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0315","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer","volume":"18","author":"Roden","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0320","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1128\/jvi.71.8.6247-6252.1997","article-title":"Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope","volume":"71","author":"Roden","year":"1997","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-3-83","article-title":"Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33","volume":"3","author":"Roth","year":"2006","journal-title":"Virol. J."},{"issue":"8","key":"10.1016\/j.gene.2021.145533_b0330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/v9080229","article-title":"Targeting persistent human papillomavirus infection","volume":"9","author":"Shanmugasundaram","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.gene.2021.145533_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00489","article-title":"Abundance of HPV L1 intra-genotype variants with capsid epitopic modifications found within low-and high-grade Pap smears with potential implications for vaccinology","volume":"10","author":"Shen-Gunther","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.gene.2021.145533_b0340","doi-asserted-by":"crossref","unstructured":"Tong, Y., Tonui, P., Ermel, A., Orang\u2019o, O., Wong, N., Titus, M., Kiptoo, S., Muthoka, K., Loehrer, P.J., Brown, D.R., 2020. Persistence of oncogenic and non-oncogenic human papillomavirus is associated with human immunodeficiency virus infection in Kenyan women.SAGE Open Med. 8, 2050312120945138.","DOI":"10.1177\/2050312120945138"},{"issue":"1\u20132","key":"10.1016\/j.gene.2021.145533_b0345","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.virusres.2006.07.012","article-title":"A deletion and point mutation study of the human papillomavirus type 16 major capsid gene","volume":"122","author":"Varsani","year":"2006","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0100-879X2005000100001","article-title":"L1 sequence of a new human papillomavirus type-58 variant associated with cervical intraepithelial neoplasia","volume":"38","author":"Veras","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"10","key":"10.1016\/j.gene.2021.145533_b0355","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cam4.496","article-title":"Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without Chlamydia trachomatis co-infection","volume":"4","author":"Vriend","year":"2015","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.gene.2021.145533_b0360","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/erv.12.151","article-title":"Virus-like particles for the prevention of human papillomavirus-associated malignancies","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev. Vaccines"},{"issue":"6","key":"10.1016\/j.gene.2021.145533_b0365","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1128\/JVI.73.6.4882-4889.1999","article-title":"Characterization of a major neutralizing epitope on human papillomavirus type 16 L1","volume":"73","author":"White","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.gene.2021.145533_b0370","unstructured":"WHO, World Health Organization, Guide to introducing HPV vaccine into national immunization programmes, 2016."},{"key":"10.1016\/j.gene.2021.145533_b0375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.gene.2018.01.037","article-title":"Human papillomavirus (HPV) 18 genetic variants and cervical cancer risk in Taizhou area, China","volume":"647","author":"Xu","year":"2018","journal-title":"Gene"},{"issue":"11","key":"10.1016\/j.gene.2021.145533_b0380","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00705-006-0798-8","article-title":"Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes","volume":"151","author":"Xu","year":"2006","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0385","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/v12010018","article-title":"Virus-like particle-based L2 vaccines against HPVs: where are we today?","volume":"12","author":"Yadav","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0390","first-page":"337","article-title":"Variant sublineages of human papillomavirus type 16 predispose women to persistent infection characterized by a sequence analysis of the E6, L1, and LCR regions","volume":"12","author":"Yang","year":"2019","journal-title":"Int. J. Clin. Exp. Path."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0395","doi-asserted-by":"crossref","first-page":"e55204","DOI":"10.1371\/journal.pone.0055204","article-title":"Genetic variability in L1 and L2 genes of HPV-16 and HPV-58 in Southwest China","volume":"8","author":"Yue","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.gene.2021.145533_b0400","first-page":"5498","article-title":"Genetic variability in E5, E6, E7 and L1 genes of human papillomavirus type 31","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.gene.2021.145533_b0405","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.gene.2016.03.007","article-title":"Genetic variability in E6, E7, and L1 genes of human papillomavirus genotype 52 from Southwest China","volume":"585","author":"Zhang","year":"2016","journal-title":"Gene"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037811192100127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037811192100127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:40:39Z","timestamp":1759855239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037811192100127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":83,"alternative-id":["S037811192100127X"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2021.145533","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2021.145533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"145533"}}